Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SHC 
Sotera Health Co (SHC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SHC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16
1 Year Target Price $16
| 3 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.87% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.63B USD | Price to earnings Ratio 181.11 | 1Y Target Price 16 |
Price to earnings Ratio 181.11 | 1Y Target Price 16 | ||
Volume (30-day avg) 8 | Beta 1.84 | 52 Weeks Range 9.53 - 16.99 | Updated Date 09/17/2025 |
52 Weeks Range 9.53 - 16.99 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.14% | Operating Margin (TTM) 35.34% |
Management Effectiveness
Return on Assets (TTM) 7.24% | Return on Equity (TTM) 5.14% |
Valuation
Trailing PE 181.11 | Forward PE 20.2 | Enterprise Value 6647236677 | Price to Sales(TTM) 4.12 |
Enterprise Value 6647236677 | Price to Sales(TTM) 4.12 | ||
Enterprise Value to Revenue 5.91 | Enterprise Value to EBITDA 16.02 | Shares Outstanding 284047008 | Shares Floating 139276572 |
Shares Outstanding 284047008 | Shares Floating 139276572 | ||
Percent Insiders 2.46 | Percent Institutions 90.59 |
Upturn AI SWOT
Sotera Health Co
Company Overview
History and Background
Sotera Health was formed in 2017 when GTCR, a private equity firm, acquired STERIS Corporation's sterilization services division. It is a global provider of sterilization and lab testing services.
Core Business Areas
- Sterilization Services: Providing contract sterilization services utilizing gamma irradiation, electron beam, and ethylene oxide technologies.
- Lab Testing Services: Offering microbiological and analytical testing services for medical devices and pharmaceutical products.
- Nordion: Supplying Cobalt-60 used in gamma sterilization.
Leadership and Structure
The leadership team includes Michael Petras Jr. (Chairman, President, and CEO). The company has a traditional corporate structure with distinct business units and functional departments.
Top Products and Market Share
Key Offerings
- Gamma Sterilization: Utilizes Cobalt-60 to sterilize medical devices and other products. Sotera Health is a major player in this market. Key competitors include Steris and Griffith Foods. Accurate market share data is difficult to ascertain but Sotera Health and Steris dominate.
- Electron Beam (E-Beam) Sterilization: Employs accelerated electrons for sterilization. Competitors include Steris and other smaller regional providers. Accurate market share data is difficult to ascertain but Sotera Health and Steris dominate.
- Ethylene Oxide (EtO) Sterilization: Uses EtO gas for sterilization, suitable for heat-sensitive materials. Sotera Health, Steris, and smaller regional players. Concerns regarding EtO emissions have resulted in regulatory challenges. Accurate market share data is difficult to ascertain but Sotera Health and Steris dominate.
- Lab Testing Services: Offers microbiological and analytical testing services. The competitors are Nelson Laboratories (Steris), WuXi AppTec, and Eurofins Scientific. The company generates significant revenue from this division.
Market Dynamics
Industry Overview
The sterilization and lab testing market is driven by increasing demand for medical devices and pharmaceuticals, stringent regulatory requirements, and growing awareness of infection control.
Positioning
Sotera Health is a leading provider with a broad service portfolio and a global footprint, giving it a competitive advantage in serving large medical device and pharmaceutical companies.
Total Addressable Market (TAM)
The global sterilization services market is estimated to be around $8 billion. Sotera Health is positioned to capture a significant portion of this TAM through its comprehensive service offerings.
Upturn SWOT Analysis
Strengths
- Leading market position
- Broad service portfolio
- Global network
- Strong relationships with medical device and pharmaceutical companies
Weaknesses
- Dependence on EtO sterilization (regulatory risk)
- Litigation risk related to EtO emissions
- Sensitivity to economic cycles
Opportunities
- Growing demand for sterilization services
- Expansion into emerging markets
- Development of new sterilization technologies
- Increasing outsourcing of lab testing services
Threats
- Stringent regulatory requirements
- Environmental concerns regarding EtO emissions
- Competition from other sterilization providers
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- STERIS (STE)
- Nelson Laboratories (part of STERIS)
- WuXi AppTec (2359.HK)
Competitive Landscape
Sotera Health competes with STERIS and smaller regional providers. The company's broad service portfolio and global presence give it a competitive advantage.
Major Acquisitions
Nelson Laboratories
- Year: 2021
- Acquisition Price (USD millions): 1300
- Strategic Rationale: Expanded lab testing capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by organic expansion and acquisitions.
Future Projections: Analyst estimates suggest continued growth in revenue, driven by increasing demand for sterilization and lab testing services. The estimations are moderate
Recent Initiatives: Focus on operational efficiencies, investments in new technologies, and expansion of service offerings.
Summary
Sotera Health is a leading provider of sterilization and lab testing services, benefiting from a strong market position and a broad service portfolio. Its dependence on EtO sterilization and the associated regulatory and litigation risks pose challenges. The company has been trying to grow organically and through acquisitions, but needs to manage the risks associated with EtO more effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Market share figures are estimates and may not be precise. The financial data is not accessible, affecting accuracy.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sotera Health Co
Exchange NASDAQ | Headquaters Broadview Heights, OH, United States | ||
IPO Launch date 2020-11-20 | Chairman & CEO Mr. Michael B. Petras Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 3000 | Website https://soterahealth.com |
Full time employees 3000 | Website https://soterahealth.com | ||
Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.